Play all audios:
Access through your institution Buy or subscribe Bell, K. J. _ et al_. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of
trial data. _BMJ_ 338, b2266 (2009). “Monitoring bone mineral density (BMD) in the first 3 years after starting postmenopausal women on a potent bisphosphonate is unnecessary and may be
misleading,” says Katy Bell from the University of Sydney, Australia. Bell _ et al_. question the value of BMD monitoring in this population in a new study published in the _British Medical
Journal_. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online
access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which
are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support Authors * Lisa Richards View author
publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Richards, L. Monitoring BMD
after bisphosphonate treatment: is it worth it?. _Nat Rev Rheumatol_ 5, 470 (2009). https://doi.org/10.1038/nrrheum.2009.129 Download citation * Issue Date: September 2009 * DOI:
https://doi.org/10.1038/nrrheum.2009.129 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not
currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative